Back to Browse Journals » Drug Design, Development and Therapy » Volume 7

Risk factors in patients with AFB smear-positive sputum who receive inappropriate antituberculous treatment

Authors Chang CY, Hong JY, Yuan MK, Chang SJ, Lee YM, Chang SC, Hsu LC, Cheng SL

Published Date January 2013 Volume 2013:7 Pages 53—58


Received 16 October 2012, Accepted 21 November 2012, Published 31 January 2013

Cheng-Yu Chang,1,* Jen-Yee Hong,2,* Mei-Kang Yuan,3,4 Shu-Ju Chang,5 Yuan-Ming Lee,6 Shih-Chieh Chang,2,4 Li-Cho Hsu,2,* Shin-Lung Cheng1

1Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan; 2Department of Internal Medicine, 3Department of Radiology, 4Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; 5Department of Industrial Management and Enterprise Information, Aletheia University, Taipei, Taiwan; 6Department of Laboratory Medicine, National Yang-Ming University Hospital, Yilan, Taiwan

*These authors contributed equally to this work

Background: Acid-fast bacilli (AFB) smear-positive sputum is usually an initial clue in the diagnosis of pulmonary tuberculosis (TB); however, the test is not disease-specific. Nontuberculous mycobacterium-related colonization or lung disease often has AFB smear-positive sputum results, and physicians may prescribe unnecessary antituberculous drugs for these patients. The aim of this study was to analyze the clinical characteristics of patients with AFB smear-positive sputum who received unnecessary anti-TB treatment.
Methods and patients: From January 2008 to July 2011, we retrospectively enrolled 97 patients with AFB smear-positive sputum who did not have pulmonary TB according to mycobacterial cultures and clinical judgment. We analyzed the clinical and radiographic features of the patients who received inappropriate and unnecessary anti-TB treatment. Preliminary analyses of chi-square and Fisher's exact tests were applied to determine factors unlikely to be associated with the independent variables. The relationship between independent covariates was then analyzed using multivariate logistic regression.
Results: Of the 97 enrolled patients, 25 (25.8%) were diagnosed with pulmonary TB and prescribed anti-TB drugs (mostly a combination of isoniazid, rifampicin, ethambutol, and pyrazinamide). The other 72 (74.2%) patients were not initially diagnosed with pulmonary TB and were classified as the control group. Compared to the control group, the patients who received inappropriate anti-TB treatment had more chronic cough as presentation symptom and heavy AFB Ziehl–Neelsen staining in sputum (>10/100 fields, grading 2+ to 4+). There were no significant differences in the radiographic analysis between the two groups.
Conclusion: Among the patients with AFB smear-positive sputum that did not have pulmonary TB, chronic cough and heavy AFB staining (2+ to 4+) were risk factors for the inappropriate administration of unnecessary anti-TB treatment.

Keywords: AFB smear-positive sputum, Mycobacterium tuberculosis, antituberculous treatment

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R

Drug Design, Development and Therapy 2013, 7:339-348

Published Date: 15 April 2013

Current and emerging pharmacological treatments for sarcoidosis: a review

Beegle SH, Barba K, Gobunsuy R, Judson MA

Drug Design, Development and Therapy 2013, 7:325-338

Published Date: 12 April 2013

Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

Liu L, Ma Y, Wang RL, Xu WR, Wang SQ, Chou KC

Drug Design, Development and Therapy 2013, 7:279-288

Published Date: 8 April 2013

Phentermine and topiramate for the management of obesity: a review

Cosentino G, Conrad AO, Uwaifo GI

Drug Design, Development and Therapy 2013, 7:267-278

Published Date: 5 April 2013

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

Palfreeman AC, McNamee KE, McCann FE

Drug Design, Development and Therapy 2013, 7:201-210

Published Date: 27 March 2013

Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation

Wu X, Hayes D Jr, Zwischenberger JB, Kuhn RJ, Mansour HM

Drug Design, Development and Therapy 2013, 7:59-72

Published Date: 4 February 2013

New treatments for myasthenia: a focus on antisense oligonucleotides

Angelini C, Martignago S, Bisciglia M

Drug Design, Development and Therapy 2013, 7:13-17

Published Date: 10 January 2013